UBS Group’s Acurx Pharmaceuticals ACXP Stock Holding History

UBS Group’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5	Sell	3 -6,309	-100%	-$13.1K	﹤0.01%	10345
2026 Q1	$23.4K	Buy	6,312 +6,143	+3,635%	+$17.4K	﹤0.01%	7827
2025 Q4	$420	Buy	+169	New	+$810	﹤0.01%	9975
2025 Q3	–	Sell	-1,938	Closed	-$19.8K	–	10286
2025 Q2	$19.8K	Buy	1,938 +1,936	+96,800%	+$15.6K	﹤0.01%	8450
2025 Q1	$18	Sell	2 -296	-99%	-$3.99K	﹤0.01%	10098
2024 Q4	$4.85K	Buy	+298	New	+$8.97K	﹤0.01%	8719
2024 Q3	–	Sell	-44	Closed	-$1.98K	–	9444
2024 Q2	$1.98K	Buy	+44	New	+$1.93K	﹤0.01%	8447
2023 Q2	–	Sell	-145	Closed	-$10K	–	8823
2023 Q1	$10K	Buy	145 +8	+6%	+$583	﹤0.01%	7612
2022 Q4	$10.9K	Sell	137 -67	-33%	-$4.41K	﹤0.01%	8463
2022 Q3	$12K	Buy	204 +152	+292%	+$11.4K	﹤0.01%	8135
2022 Q2	$4K	Buy	+52	New	+$3.5K	﹤0.01%	9025

Other funds holding ACXP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $197M AUM 24.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

UBS Group's ACXP Position: Q2 2026 in Review

UBS Group reduced its Acurx Pharmaceuticals (ACXP) stake by 100% in Q2 2026, selling an estimated $13.1K and leaving 3 shares worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #10345.

UBS Group first reported a position in ACXP in Q2 2022 and has held it in 11 quarters since. The position peaked at $23.4K in Q1 2026. 19 funds tracked by Wall St. Rank hold ACXP as of Q2 2026.

UBS Group held 3 shares of Acurx Pharmaceuticals worth $5 as of Q2 2026.
UBS Group sold 6,309 Acurx Pharmaceuticals shares in Q2 2026, an estimated $13.1K.
Acurx Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10345 holding.
UBS Group first reported a position in Acurx Pharmaceuticals in Q2 2022 and has held it in 11 quarters since.
UBS Group's Acurx Pharmaceuticals position peaked at $23.4K in Q1 2026.
19 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.